ImmunityBio's Anktiva Receives EU Approval, Boosting Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 hours ago
0mins
Should l Buy IBRX?
Source: stocktwits
- Anktiva Approval: ImmunityBio (IBRX) received conditional marketing authorization for Anktiva across 33 countries, boosting its market valuation to nearly $6.9 billion with a 287% stock price increase, highlighting its strong growth potential in cancer treatment.
- Adlai Nortye Clinical Progress: Adlai Nortye (ANL) dosed its first U.S. patient in the global AN9025 trial, leading to a 387% stock price surge and a market cap of $216.16 million, indicating significant advancements in its oncology strategy.
- Erasca Global Strategy: Erasca (ERAS) secured worldwide rights to ERAS-0015, resulting in a 335% stock price increase and a market cap exceeding $4.6 billion, reflecting its potential in cancer drug development with promising early clinical responses.
- Investor Sentiment Fluctuations: While IBRX experienced volatile investor sentiment, ANL's shifted from extremely bullish to neutral, and ERAS remained bearish, yet overall interest in these biotech firms increased, indicating sustained market engagement.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.660
Low
5.00
Averages
7.33
High
9.00
Current: 6.660
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio's Global Expansion and Balance Sheet Strengthening
- Balance Sheet Strengthening: Founder Patrick Soon-Shiong indicated plans to strengthen the balance sheet and prepare for global expansion, despite recent stock price impacts from an FDA warning letter, the company is focused on achieving long-term growth.
- European Expansion Talks: Soon-Shiong mentioned discussions with a European health minister aimed at advancing 'immunotherapy 2.0', which will help the company promote NK cell and CD8 T-cell-based therapies in new markets, enhancing its competitive position.
- Declining Short Interest: Short interest in IBRX has decreased from 13.7% in mid-February to 12.9%, reflecting increased market confidence in the Anktiva therapy, especially after receiving conditional marketing authorization from the EU.
- FDA Warning Impact: Although the FDA issued a warning regarding Anktiva's promotional claims, leading to a short-term stock drop, the company is actively advancing clinical trials for new indications, demonstrating resilience and potential in the market.
See More
ImmunityBio's Anktiva Receives EU Approval, Boosting Stock
- Anktiva Approval: ImmunityBio (IBRX) received conditional marketing authorization for Anktiva across 33 countries, boosting its market valuation to nearly $6.9 billion with a 287% stock price increase, highlighting its strong growth potential in cancer treatment.
- Adlai Nortye Clinical Progress: Adlai Nortye (ANL) dosed its first U.S. patient in the global AN9025 trial, leading to a 387% stock price surge and a market cap of $216.16 million, indicating significant advancements in its oncology strategy.
- Erasca Global Strategy: Erasca (ERAS) secured worldwide rights to ERAS-0015, resulting in a 335% stock price increase and a market cap exceeding $4.6 billion, reflecting its potential in cancer drug development with promising early clinical responses.
- Investor Sentiment Fluctuations: While IBRX experienced volatile investor sentiment, ANL's shifted from extremely bullish to neutral, and ERAS remained bearish, yet overall interest in these biotech firms increased, indicating sustained market engagement.
See More
ImmunityBio Investors Reminder for Class Action Lawsuit
- Lawsuit Deadline: Investors must file Lead Plaintiff applications by May 26, 2026, if they purchased ImmunityBio securities between January 19 and March 24, 2026, indicating the legal risks and potential liabilities the company faces.
- FDA Warning Letter Impact: On March 24, 2026, the FDA issued a warning letter to CEO Richard Adcock, stating that misleading claims in advertisements about Anktiva led to a 21% drop in share price, losing $1.98 per share, reflecting market concerns over the company's compliance.
- Legal Allegations Context: ImmunityBio and its executives are accused of failing to disclose material information during the class period, violating federal securities laws, which could expose investors to economic losses and further damage the company's reputation and market trust.
- Law Firm's Role: Kahn Swick & Foti, LLC, as the plaintiff law firm, reminds investors of their rights in the securities class action, showcasing the firm's expertise and influence in securities litigation, potentially providing legal support and recovery opportunities for investors.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading efficacy claims made by Chairman Soon-Shiong regarding Anktiva during a podcast, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Class Action Lawsuit Initiated: Hagens Berman has filed a securities class action lawsuit against ImmunityBio on behalf of investors who purchased securities between January 19 and March 24, 2026, alleging violations of federal securities laws that could lead to significant losses for investors.
- Efficacy Claims Controversy: Soon-Shiong's assertion that Anktiva can treat all cancers has been flagged by the FDA as lacking data support, misleading the public into believing the drug can cure all cancers, further damaging the company's reputation and trustworthiness.
- Investor Rights Protection: Hagens Berman is urging investors who suffered substantial losses to submit claims and encouraging witnesses to provide information to assist in the investigation, demonstrating a commitment to protecting investor rights while reflecting market concerns about the company's future prospects.
See More
ImmunityBio Faces Class Action Lawsuit Over Anktiva Claims
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces that investors who purchased ImmunityBio securities between January 19 and March 24, 2026, can seek lead plaintiff status in a class action lawsuit, indicating significant investor concern over potential fraud by the company.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter accusing ImmunityBio of misleading advertising for its Anktiva drug, resulting in a 21% drop in stock price, reflecting a sharp decline in market trust towards the company's product claims.
- False Statement Allegations: The lawsuit alleges that ImmunityBio and its executives made false statements during the class period, claiming Anktiva could make all NMIBC patients cancer-free long-term, a claim that has not been substantiated, potentially leading to substantial investor losses.
- Law Firm Strength: Robbins Geller ranked #1 in recovering over $916 million for investors in 2025, showcasing its strong capabilities in securities fraud and shareholder rights litigation, which may provide effective legal support for affected investors.
See More
ImmunityBio Secures $75M Financing from Oberland Capital
- Financing Agreement Update: ImmunityBio announced a $75 million non-dilutive financing from Oberland Capital as part of an existing royalty interest purchase agreement, increasing total capital commitment to $375 million, thereby enhancing liquidity to support the development of its cancer therapy Anktiva.
- Royalty Terms Adjustment: The terms of the deal remain unchanged except for a slight increase in the royalty payback rate, which provides the company with some flexibility for future earnings without altering the royalty cap.
- Debt Reduction Strategy: Concurrently, ImmunityBio revealed that Nant Capital converted $25 million of an outstanding promissory note into equity, resulting in the issuance of 4.6 million shares to alleviate the debt burden associated with the $505 million promissory note due in December 2024, thereby strengthening the company's financial stability.
- Market Reaction Analysis: Despite facing an FDA warning regarding Anktiva advertisements, the market's response to the financing and debt management measures remains positive, reflecting investor confidence in the company's long-term growth potential.
See More
ImmunityBio's Global Expansion and Balance Sheet Strengthening
- Balance Sheet Strengthening: Founder Patrick Soon-Shiong indicated plans to strengthen the balance sheet and prepare for global expansion, despite recent stock price impacts from an FDA warning letter, the company is focused on achieving long-term growth.
- European Expansion Talks: Soon-Shiong mentioned discussions with a European health minister aimed at advancing 'immunotherapy 2.0', which will help the company promote NK cell and CD8 T-cell-based therapies in new markets, enhancing its competitive position.
- Declining Short Interest: Short interest in IBRX has decreased from 13.7% in mid-February to 12.9%, reflecting increased market confidence in the Anktiva therapy, especially after receiving conditional marketing authorization from the EU.
- FDA Warning Impact: Although the FDA issued a warning regarding Anktiva's promotional claims, leading to a short-term stock drop, the company is actively advancing clinical trials for new indications, demonstrating resilience and potential in the market.
See More
ImmunityBio's Anktiva Receives EU Approval, Boosting Stock
- Anktiva Approval: ImmunityBio (IBRX) received conditional marketing authorization for Anktiva across 33 countries, boosting its market valuation to nearly $6.9 billion with a 287% stock price increase, highlighting its strong growth potential in cancer treatment.
- Adlai Nortye Clinical Progress: Adlai Nortye (ANL) dosed its first U.S. patient in the global AN9025 trial, leading to a 387% stock price surge and a market cap of $216.16 million, indicating significant advancements in its oncology strategy.
- Erasca Global Strategy: Erasca (ERAS) secured worldwide rights to ERAS-0015, resulting in a 335% stock price increase and a market cap exceeding $4.6 billion, reflecting its potential in cancer drug development with promising early clinical responses.
- Investor Sentiment Fluctuations: While IBRX experienced volatile investor sentiment, ANL's shifted from extremely bullish to neutral, and ERAS remained bearish, yet overall interest in these biotech firms increased, indicating sustained market engagement.
See More
ImmunityBio Investors Reminder for Class Action Lawsuit
- Lawsuit Deadline: Investors must file Lead Plaintiff applications by May 26, 2026, if they purchased ImmunityBio securities between January 19 and March 24, 2026, indicating the legal risks and potential liabilities the company faces.
- FDA Warning Letter Impact: On March 24, 2026, the FDA issued a warning letter to CEO Richard Adcock, stating that misleading claims in advertisements about Anktiva led to a 21% drop in share price, losing $1.98 per share, reflecting market concerns over the company's compliance.
- Legal Allegations Context: ImmunityBio and its executives are accused of failing to disclose material information during the class period, violating federal securities laws, which could expose investors to economic losses and further damage the company's reputation and market trust.
- Law Firm's Role: Kahn Swick & Foti, LLC, as the plaintiff law firm, reminds investors of their rights in the securities class action, showcasing the firm's expertise and influence in securities litigation, potentially providing legal support and recovery opportunities for investors.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading efficacy claims made by Chairman Soon-Shiong regarding Anktiva during a podcast, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Class Action Lawsuit Initiated: Hagens Berman has filed a securities class action lawsuit against ImmunityBio on behalf of investors who purchased securities between January 19 and March 24, 2026, alleging violations of federal securities laws that could lead to significant losses for investors.
- Efficacy Claims Controversy: Soon-Shiong's assertion that Anktiva can treat all cancers has been flagged by the FDA as lacking data support, misleading the public into believing the drug can cure all cancers, further damaging the company's reputation and trustworthiness.
- Investor Rights Protection: Hagens Berman is urging investors who suffered substantial losses to submit claims and encouraging witnesses to provide information to assist in the investigation, demonstrating a commitment to protecting investor rights while reflecting market concerns about the company's future prospects.
See More
ImmunityBio Faces Class Action Lawsuit Over Anktiva Claims
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces that investors who purchased ImmunityBio securities between January 19 and March 24, 2026, can seek lead plaintiff status in a class action lawsuit, indicating significant investor concern over potential fraud by the company.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter accusing ImmunityBio of misleading advertising for its Anktiva drug, resulting in a 21% drop in stock price, reflecting a sharp decline in market trust towards the company's product claims.
- False Statement Allegations: The lawsuit alleges that ImmunityBio and its executives made false statements during the class period, claiming Anktiva could make all NMIBC patients cancer-free long-term, a claim that has not been substantiated, potentially leading to substantial investor losses.
- Law Firm Strength: Robbins Geller ranked #1 in recovering over $916 million for investors in 2025, showcasing its strong capabilities in securities fraud and shareholder rights litigation, which may provide effective legal support for affected investors.
See More
ImmunityBio Secures $75M Financing from Oberland Capital
- Financing Agreement Update: ImmunityBio announced a $75 million non-dilutive financing from Oberland Capital as part of an existing royalty interest purchase agreement, increasing total capital commitment to $375 million, thereby enhancing liquidity to support the development of its cancer therapy Anktiva.
- Royalty Terms Adjustment: The terms of the deal remain unchanged except for a slight increase in the royalty payback rate, which provides the company with some flexibility for future earnings without altering the royalty cap.
- Debt Reduction Strategy: Concurrently, ImmunityBio revealed that Nant Capital converted $25 million of an outstanding promissory note into equity, resulting in the issuance of 4.6 million shares to alleviate the debt burden associated with the $505 million promissory note due in December 2024, thereby strengthening the company's financial stability.
- Market Reaction Analysis: Despite facing an FDA warning regarding Anktiva advertisements, the market's response to the financing and debt management measures remains positive, reflecting investor confidence in the company's long-term growth potential.
See More
